Cervical cancer vaccine shows promise

PHILADELPHIA — A vaccine against cervical cancer, being developed by Inovio Pharmaceuticals Inc. of Blue Bell, Pa., produced positive results in a small sample of 18 women.

The vaccine prompted their bodies to produce T cells — a type of white blood cells — that, in a separate lab test, recognized cells with tumor proteins, and killed them.

The researchers, including a team from the University of Pennsylvania, say the paper in the journal Science is the first to show that a DNA vaccine alone produced a high level of immunity in people. At the same time, the researchers acknowledged that a working vaccine faces more trials and remains years away from an actual product.

Cervical cancer is the second most common type — after breast cancer — in women worldwide. Every year, about 470,000 women are diagnosed with cervical cancer. About half of them, mostly in developing countries, eventually die.

Unlike other cancers, it is caused by infection — in this case, some types of human papillomavirus, which also causes genital warts.

Vaccines to prevent HPV infection have been developed — Gardasil, by Merck &Co., and Cervarix, by GlaxoSmithKine.

“The problem is, the vaccines don’t protect or help women who are already infected with the virus,” said J. Joseph Kim, CEO of Inovio, which funded the study. He and several Inovio scientists participated in it.

In the United States, only about three in 10 teenage girls — the target group – are fully vaccinated, and many fewer in developing countries. Plus, many women were infected before the two vaccines were developed. Researchers have estimated that between 28 million and 40 million women worldwide have pre-cancerous HPV infections.

In the initial trial for the Inovio vaccine, called VGX-3100, 18 women who had been treated previously for lesions were injected with a vaccine made of DNA carrying a genetic code targeted to prompt the body to make a specific kind of T cell.

Those T cells were then removed and combined in a test tube with other cells from the women that displayed the tumor protein. In the lab setting, the T cells attacked and killed the other cells.

The results were exciting for David B. Weiner, a Penn professor of pathology and laboratory medicine, who also participated in the study.

“The T cells’ ability to recognize and kill those targets in the lab suggests that they would now be able to do this against the women’s own cancer cells in their bodies,” he said.

Weiner’s lab pioneered the use of DNA vaccines, a research field that looked promising 20 years ago, partly because things that may have side effects can be eliminated. They are nonlive, so there’s no risk of them causing the disease. They don’t replicate in the body.

But in the late 1990s, interest in the new vaccines flagged. In tests on larger animals and humans, the immune response was disappointing.

Now, said Weiner, “basically, this is the first paper that we’re aware of that demonstrates that a DNA vaccine on its own in humans could produce this quality or magnitude of immunity.”

“It opens up a lot of exciting avenues of study,” he added. In the paper, Weiner reported compensation from Inovio and other drug companies.

One of the differences this time is that the vaccine was delivered along with a small electric pulse, believed to greatly increase the efficiency of the vaccine.

Stanley A. Plotkin, an emeritus professor at Penn whose career has been in vaccine development, said the study is important because vaccines have traditionally been prophylactic, preventing the disease before it occurs.

“In this case,” he said, “we’re talking about therapeutic vaccines, used in people who already have a disease in order to eliminate it or to control it.”

Also, he said, the current research goes a long way toward “making a DNA vaccine practical and useful in humans, rather than only in animal models.”

Plotkin, a co-discoverer of the rotovirus vaccine, is a consultant to vaccine manufacturers, including Inovio, but was not involved in the study.

Most side effects of the vaccine were minimal and deemed unrelated to the treatment, the Science paper reported.

After nine months – the official conclusion of the study – the participants were still producing T cells, Kim said. However, he said, the effect seems to be more durable than that. Tests up to three years later showed the vaccination was still working.

Inovio is currently conducting phase II trials on about 150 women worldwide who have untreated precancerous lesions. Kim said the results of that study are expected by the end of 2013.

Kim said it could be four to six years before the vaccine, if it ultimately proves effective, could be commercially available.

Talk to us

More in Local News

Construction crews demolish public housing  homes at the Baker Heights in Everett’s Delta Neighborhood on Tuesday, June 8, 2021 in Everett, Washington.  (Chuck Taylor / The Herald)
Baker Heights site no longer on the table for WSU expansion

As demolition proceeds, it’s unclear what the Everett Housing Authority will do with roughly 10 acres.

Rick Steves has supported a number of local projects with donations of $1 million or more.  (Dan Bates / The Herald)
Travel guru Rick Steves will be Edmonds parade grand marshal

The Edmonds Chamber was finally able to honor the native son now that the pandemic is keeping him home.

Detectives investigate killing of woman, 23, in Smokey Point

She had “obvious signs of trauma,” according to the sheriff’s office. A 25-year-old man was arrested.

Woman injured after shooting at south Everett 7-Eleven

She was taken to a hospital and was expected to survive. The suspects fled the scene.

Vandalism in Lake Stevens prompts city to install cameras

Park bathrooms have been the main targets. The mayor hopes surveillance and watchful citizens will be deterrents.

FILE - In this May 26, 2020, file photo, a sign at the headquarters for the Washington state Employment Security Department is shown at the Capitol in Olympia, Wash. Washington state's rush to get unemployment benefits to residents who lost jobs due to the coronavirus outbreak left it vulnerable to criminals who made off with hundreds of millions of dollars in fraudulent claims. (AP Photo/Ted S. Warren, File)
State’s unemployment recipients must look for work after July 4

The change comes after Washington reported the third straight weekly decline in jobless claims.

One-time payments of $1,250 proposed for some county workers

Another proposal by County Executive Somers would boost hourly pay by $4 for grocery store workers.

A house fire displaced seven people and killed one dog Saturday, June 12, 2021, on Chain Lake Road in Monroe. (Snohomish Regional Fire & Rescue)
7 displaced as family escapes Monroe house fire, dog killed

People honked to alert three occupants of the home to flames Saturday morning.

Shinji Maeda steps out of his plane waving American and Japanese flags after completing his round-the-world tour that took him to 18 different countries on Friday, June 11, 2021 in Snohomish, Wa. (Olivia Vanni / The Herald)
After 22,000 miles and 18 countries, he landed in Snohomish

Partially blind Japanese native Shinji Maeda came to the U.S. to become an aviator. Then he toured the world.

Most Read